CDD news

June 27, 2017

Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection

CP101 is the lead, orally-administered product generated from Crestovo’s Full-Spectrum MicrobiotaTM (FSMTM) platform PRISM 3 includes 240 patients at clinical sites with broad coverage throughout the U.S. The company is based on foundational clinical research from gut microbiota-based treatment pioneers, Dr. Thomas J. Borody, Dr. Alexander Khoruts and Dr. Michael J. Sadowsky June 27, 2017 […]

CDD news
June 6, 2017

Microbiome leader Professor Borody calls for a National Australian FMT Bank to fight Drug Resistant Diseases

SYDNEY, AUS, May 19, 2017 – (ACN Newswire) – Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) has called for a national faecal bank to fight drug resistant and epidemic diseases in hospitals and clinics across the country. Professor Borody, the Founder and Medical Director of the Centre for Digestive Diseases (CDD) in […]

CDD news
September 15, 2016

Fecal Microbiota Transplant Induces Steroid-free Remission in Ulcerative Colitis Patients, Study Reports

A clinical study found that multi-donor fecal microbiota transplantation (FMT) successfully induced clinical and endoscopic remission in patients with resistant active ulcerative colitis (UC). Results from the placebo-controlled trial were presented at the recent 11th Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Amsterdam, the Netherlands. Read more 

CDD news